TWIRLA Drug Patent Profile

Which patents cover Twirla, and what generic alternatives are available?

Twirla is a drug marketed by Agile and is included in one NDA. There are three patents protecting this drug.

This drug has nineteen patent family members in twelve countries.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

DrugPatentWatch^® Generic Entry Outlook for Twirla

There are two tentative approvals for the generic drug (ethinyl estradiol; levonorgestrel), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for TWIRLA

International Patents:	19
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	5
Drug Prices:	Drug price information for TWIRLA
What excipients (inactive ingredients) are in TWIRLA?	TWIRLA excipients list
DailyMed Link:	TWIRLA at DailyMed

See drug prices for TWIRLA

Pharmacology for TWIRLA

Drug Class	Estrogen Progestin Progestin-containing Intrauterine System
Mechanism of Action	Estrogen Receptor Agonists
Physiological Effect	Inhibit Ovum Fertilization

US Patents and Regulatory Information for TWIRLA

TWIRLA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020		RX	Yes	Yes			Y
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020		RX	Yes	Yes			Y
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020		RX	Yes	Yes			Y

Expired US Patents for TWIRLA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020

International Patents for TWIRLA

When does loss-of-exclusivity occur for TWIRLA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hong Kong

Japan

New Zealand

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TWIRLA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	030037	SISTEMA DE ADMINISTRACION DE ANTICONCEPTIVO TRANSDERMICO MEJORADO Y EL USO DE UNA CAPA DE SOPORTE Y UNA MATRIZ POLIMERICA PARA LA FABRICACION DE UN SISTEMA DE ADMINISTRACION DE ANTICONCEPTIVO
Austria	453374
Australia	1788301	Improved transdermal contraceptive delivery system and process
Australia	2004253593	Transdermal hormone delivery system: compositions and methods
Australia	2006201918	Improved transdermal contraceptive delivery system and process

Supplementary Protection Certificates for TWIRLA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0398460	C300221	Netherlands		PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
1214076	C01214076/01	Switzerland		PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129

Twirla Market Dynamics and Financial Trajectory

Last updated: August 4, 2026

Twirla is a prescription combined hormonal contraceptive patch marketed in the United States by Agile Therapeutics. The product generated commercial growth after its February 2021 launch, but its financial profile remained dependent on prescription expansion, insurance coverage, and continued external capital. Twirla competes with oral contraceptives, long-acting reversible contraceptives, vaginal rings, and the older Xulane patch.

Public company filings through fiscal 2023 show rising product revenue but continuing operating losses. Twirla’s principal commercial advantages are weekly dosing, a lower daily estrogen exposure than some legacy patch products, and availability as a nonoral contraceptive. Its principal constraints are the FDA label limitation for patients with body mass index of 30 kg/m² or higher, venous thromboembolism risk associated with combined hormonal contraception, reimbursement friction, and the breadth of lower-cost generic alternatives.

What is Twirla and how does it work?

Twirla contains levonorgestrel and ethinyl estradiol and delivers both hormones through the skin. It is indicated for the prevention of pregnancy in females of reproductive potential.

The patch is applied weekly for three consecutive weeks, followed by one patch-free week. The product is supplied in a transdermal system containing 120 mcg of levonorgestrel and 30 mcg of ethinyl estradiol, with a nominal daily delivery rate of approximately 120 mcg and 30 mcg, respectively.[1]

Twirla differs from oral contraceptives because it avoids gastrointestinal administration and daily pill-taking. It differs from Xulane because the products use different hormone quantities, patch technologies, and labeling.

What FDA limitations affect Twirla demand?

The FDA label states that Twirla is less effective in females with a body mass index of 30 kg/m² or greater. The label also carries boxed warnings covering cigarette smoking and serious cardiovascular events, as well as contraindications related to thrombotic disease and other estrogen-associated risks.[1]

The BMI limitation is commercially significant because obesity prevalence is high in the U.S. reproductive-age population. It narrows the addressable market and can lead prescribers to favor non-estrogen methods, intrauterine devices, implants, progestin-only methods, or oral alternatives.

When did Twirla launch and what is its FDA regulatory status?

The FDA approved Twirla in December 2020 under New Drug Application 022684.[2] Agile began commercial sales in early 2021.

Milestone	Date
FDA approval	December 2020
Commercial launch	February 2021
Dosage form	Weekly transdermal patch
Active ingredients	Levonorgestrel and ethinyl estradiol
Regulatory pathway	Full NDA approval
Primary market	United States
Current product category	Prescription combined hormonal contraceptive

Twirla is not a biologic and does not face biosimilar competition. Any future direct copy would proceed through the abbreviated new drug application pathway if the FDA determines that an equivalent product can be approved under the applicable regulatory framework. The regulatory and technical complexity of demonstrating transdermal delivery equivalence is greater than for a conventional immediate-release tablet.

How has Twirla revenue developed?

Twirla revenue has increased from a small post-launch base. Agile’s filings reported approximately $22 million in net product sales in 2022 and approximately $32 million in 2023, representing growth of roughly 45% year over year.[3]

Fiscal year	Approximate Twirla net product sales	Commercial interpretation
2020	Pre-commercial	FDA approval year
2021	Approximately $12 million	Initial launch and market-access buildout
2022	Approximately $22 million	Wider prescribing and payer expansion
2023	Approximately $32 million	Continued prescription growth

The growth rate was stronger than the absolute revenue base. Twirla remained a subscale branded pharmaceutical product relative to established contraceptive franchises. Revenue growth did not translate into sustained profitability because Agile continued to incur selling, marketing, medical-affairs, manufacturing, public-company, and research expenses.

The most important financial distinction is between product-market traction and corporate earnings. Twirla demonstrated increasing demand, but the company had not reached a stable cash-generating scale by the end of the reported 2023 period.[3]

What drove Twirla revenue growth?

The main drivers were:

1. Increased prescriber awareness after the launch period.
2. Expansion of commercial insurance coverage and pharmacy access.
3. Demand for a weekly, nonoral contraceptive.
4. Digital and telehealth prescribing channels.
5. Refill retention among patients who preferred the patch format.
6. Field sales and patient-support programs.

Revenue quality depends on the balance between gross prescription volume and net realized price. Manufacturer assistance, rebates, payer discounts, wholesaler deductions, and product returns reduce gross-to-net revenue. Contraceptive products also face sensitivity to formulary placement because patients can often substitute among multiple therapeutic methods.

How strong is Twirla’s market position?

Twirla occupies a narrow position in the broader hormonal contraceptive market. It offers a differentiated delivery system but not a new pharmacologic mechanism.

Competitor or category	Delivery	Main competitive advantage	Main Twirla challenge
Generic combined oral contraceptives	Daily oral	Low cost and broad availability	Price and prescriber familiarity
Xulane	Weekly transdermal patch	Established patch category	Direct patch competition
NuvaRing and generic equivalents	Monthly vaginal ring	Less frequent administration	Different route and patient preference
Hormonal IUDs	Long-acting intrauterine	High efficacy and duration	Procedure-based adoption
Copper IUD	Long-acting, nonhormonal	No systemic hormones	Procedure and tolerability concerns
Etonogestrel implant	Long-acting implant	Very high efficacy and duration	Insertion and removal requirements
Progestin-only methods	Oral, injectable, implant, or IUD	Avoid estrogen exposure	Different efficacy, dosing, or tolerability profile

Twirla’s strongest commercial segment is likely patients who want a weekly patch and do not qualify for, or do not prefer, long-acting methods. Its addressable market is smaller than the total contraceptive market because estrogen contraindications and the BMI warning eliminate or discourage use for many patients.

What is Twirla’s pricing and reimbursement environment?

Twirla competes against low-cost generic contraception. That creates a difficult reimbursement environment for a branded product without a new molecular entity.

Commercial success depends on whether a payer places Twirla on a preferred or accessible tier and whether prior authorization, step therapy, or higher copay requirements apply. The federal contraceptive coverage framework under the Affordable Care Act can support patient access for covered preventive services, but implementation varies by payer, plan design, and clinical circumstances.[4]

The commercial model therefore requires patient-support infrastructure. Manufacturer savings programs and coverage-navigation services can increase initiation, but they also increase the gap between gross sales and net revenue. In a contraceptive market with inexpensive generic alternatives, prescription growth alone does not establish pricing power.

What patents protect Twirla and when could generic entry occur?

Twirla’s protection consists of FDA regulatory exclusivity, Orange Book-listed patents, formulation and transdermal-delivery technology, manufacturing know-how, trademarks, and commercial scale-up experience. Twirla is not protected by biologic exclusivity and does not have the 12-year reference-product exclusivity available to biologics.

The relevant legal question is not simply the earliest patent expiration. A generic applicant could submit a Paragraph IV certification challenging an Orange Book-listed patent before expiration. The branded sponsor could then bring patent litigation, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework, subject to statutory conditions.[5]

Exclusivity or barrier	Relevance to Twirla
New chemical entity exclusivity	Not the principal protection profile for Twirla’s product
NDA regulatory exclusivity	Limited-duration protection from certain ANDA filings
Orange Book patents	May cover formulation, patch construction, drug delivery, or use
Method-of-use patents	Could cover contraceptive use or patient subgroups
Manufacturing know-how	Can complicate reliable generic patch production
Trademark protection	Protects the Twirla name, not the active ingredients
Paragraph IV challenge	Possible route for an ANDA applicant
Biosimilar pathway	Not applicable

Public FDA approval records confirm Twirla’s NDA approval, but commercial launch timing should not be confused with patent expiration. A definitive generic-entry forecast requires a current Orange Book patent listing and the relevant patent-family prosecution and litigation records. No biosimilar risk exists because Twirla is a conventional synthetic drug product.

What formulation patents matter?

Transdermal products can have protection beyond the active ingredients. Relevant technical areas may include:

• Adhesive composition and skin adhesion.
• Drug-release characteristics.
• Backing layers and protective liners.
• Hormone stability during storage.
• Manufacturing and coating processes.
• Patch wear time and dose delivery.
• Packaging and moisture protection.

These barriers can be commercially important even when they do not prevent an ANDA filing. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence, and transdermal products can present added development and manufacturing complexity compared with standard tablets.

Which companies are challenging Twirla?

The most important competitive pressure comes from established contraception manufacturers and generic drug companies rather than from a single late-stage branded challenger.

Key competitive groups include:

• Teva and other manufacturers of generic oral contraceptives.
• Mylan/Viatris and other suppliers of contraceptive products.
• Organon, Bayer, and other companies active in hormonal contraception.
• Generic or authorized-generic developers evaluating the transdermal patch category.
• Telehealth platforms that aggregate contraceptive prescribing across multiple methods.

The direct branded patch comparison is Xulane, while the broader competitive threat comes from inexpensive oral products and long-acting methods. Twirla does not need to displace all contraceptive methods to grow, but it must retain patients after initiation and obtain favorable reimbursement.

What litigation and settlement issues affect Twirla?

No major publicly established Twirla Paragraph IV litigation outcome is central to the product’s commercial history through the 2023 reporting period. The principal near-term legal risk is potential ANDA litigation involving formulation, delivery, or use patents if a generic applicant files a Paragraph IV certification.

A settlement could establish a launch date before patent expiry, subject to antitrust review and the terms of the agreement. No widely reported settlement has established a publicly recognized generic Twirla launch date through the cited period.

The absence of a public settlement date does not eliminate future entry risk. Transdermal contraception remains a technically defined product category, and the commercial value of a generic challenge would depend on manufacturing cost, expected market size, Orange Book patents, and the feasibility of demonstrating bioequivalence.

How does Twirla compare with Xulane?

Twirla and Xulane are both weekly contraceptive patches, but the products are not interchangeable without consideration of their labeling and formulation differences.

Issue	Twirla	Xulane
Hormones	Levonorgestrel and ethinyl estradiol	Norelgestromin and ethinyl estradiol
Delivery format	Weekly patch	Weekly patch
Regulatory status	FDA-approved prescription product	FDA-approved prescription product
BMI concern	Label states reduced efficacy at BMI ≥30 kg/m²	Label contains weight and BMI-related efficacy concerns
Differentiation	Different progestin and patch technology	Established category presence
Substitution	Requires product-specific prescribing and dispensing	Product-specific

Twirla’s differentiation is strongest among patients who prefer patches but seek an alternative to Xulane. Its differentiation is weaker against generic pills because the principal benefit is convenience and route of administration rather than superior contraceptive efficacy across the entire population.

What is the outlook for Twirla revenue and enterprise value?

Twirla’s commercial trajectory has three plausible stages:

Near-term growth

Prescription and net-sales growth can continue if Agile or its commercial successor expands payer access, improves patient retention, and controls customer-acquisition expense. Revenue growth from a $30 million base can still produce high percentage increases without establishing blockbuster scale.

Margin improvement

Gross margin can improve with manufacturing volume and better supply planning. Operating leverage is harder to achieve because patient-support programs, market access, sales personnel, and regulatory operations remain necessary even at moderate revenue levels.

Generic-entry exposure

A generic patch could produce a sharp price decline if it obtains broad pharmacy substitution and preferred formulary status. The impact would depend on the timing of launch, the number of entrants, patent settlements, and whether Twirla retains a clinically differentiated niche.

The primary valuation variables are net sales growth, cash burn, payer coverage, refill persistence, marketing efficiency, and the duration of effective market protection. Patent expiration alone is insufficient for valuation because an ANDA challenge could accelerate the competitive timetable.

What generic launch risks exist for Twirla?

The principal generic-entry scenarios are:

Scenario	Commercial effect
No ANDA challenge before key patent expiry	Longer branded growth period
Paragraph IV filing with litigation	Possible delay, legal expense, and settlement risk
First generic launch after litigation	Rapid price and share pressure
Multiple generic launches	More severe erosion and formulary displacement
Authorized generic or settlement launch	Earlier erosion with potentially controlled timing
Limited technical equivalence	Slower or narrower generic penetration

The risk is lower than for a simple oral tablet because transdermal delivery requires product-specific development. It is still material because generic contraception companies have extensive regulatory and commercial experience.

Key Takeaways

• Twirla is a weekly levonorgestrel/ethinyl estradiol contraceptive patch approved by the FDA in December 2020.
• Commercial launch began in February 2021.
• Net product sales increased from approximately $22 million in 2022 to approximately $32 million in 2023, based on Agile Therapeutics filings.
• The product showed commercial growth but remained financially subscale and loss-making during the reported period.
• Its market position depends on weekly dosing, nonoral administration, payer access, and patient preference.
• The FDA BMI limitation at 30 kg/m² or higher materially narrows the addressable population.
• Generic oral contraceptives, Xulane, vaginal rings, IUDs, implants, and progestin-only products are the main competitive threats.
• Biosimilar competition does not apply.
• Future ANDA and Paragraph IV activity is the key legal risk, while transdermal formulation and manufacturing complexity may slow generic development.
• Twirla’s financial upside depends on prescription retention and operating leverage, not revenue growth alone.

FAQs

Is Twirla more effective than birth-control pills?

Twirla is an effective combined hormonal contraceptive when used correctly, but its clinical effectiveness is not broadly superior to oral contraceptives. Real-world outcomes depend heavily on adherence, patch application, BMI, drug interactions, and discontinuation.

Can Twirla be used by patients with a high BMI?

The FDA label states that Twirla is less effective in females with a BMI of 30 kg/m² or greater. Prescribers must also evaluate estrogen-related contraindications and thrombotic risk.

Is Twirla covered by insurance?

Coverage varies by commercial payer and plan. The product’s market performance depends materially on formulary placement, prior authorization, copay exposure, and manufacturer assistance.

Does Twirla have biosimilar competition?

No. Twirla is a synthetic drug product, not a biologic. Any direct generic competition would use the ANDA pathway rather than the biosimilar pathway.

What would a generic Twirla do to revenue?

A broadly substitutable generic would likely reduce net price and could shift prescriptions rapidly if insurers place the generic on a preferred tier. The timing and severity would depend on Orange Book patents, Paragraph IV litigation, settlement terms, and the number of approved entrants.

References

1. U.S. Food and Drug Administration. (2020). Twirla prescribing information.
2. U.S. Food and Drug Administration. (2020). Drug approval package: Twirla NDA 022684.
3. Agile Therapeutics, Inc. (2024). Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
4. U.S. Food and Drug Administration. (n.d.). Birth control: Medicines and contraceptive devices.
5. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards.

DrugChatter Q&A for TWIRLA

Is twirla better than xulane?